Press releases

Boston Scientific Corporation (NYSE: BSX) announced today that the PROMUS™ Everolimus-Eluting Coronary Stent System has received CE Mark...

Victory supports previous court decisions related to the suit Medtronic filed against Guidant in August 2003

A live webcast and replay of the October 18 conference call will be available

FDA approval makes remote monitoring available by more than 150,000 additional patients

Gobierno de Puerto Rico aprueba el Sistema Precision, que brinda a los médicos una nueva opción de tratamiento para dolor agudo y crónico

Plans for changes consistent with HRS guidelines includes Company's commitment to the development of independent, industry-wide oversight to facilitate consistent communications, surveillance and product performance reporting practices

New cochlear implant technology to significantly increase hearing potential and quality of life for the severe-to-profoundly deaf.

CryoPlasty® Therapy may be an alternative to surgery or limb amputation

“We made progress on a number of fronts, most notably the integration of Guidant and our quality initiatives," said Jim Tobin, President and CEO.

FLEXView™ System enables physicians to perform less-invasive cardiac surgical ablation procedures

Company welcomes FDA statement that drug-eluting stents remain safe and effective when used for approved indications

NEJM editorial and articles describe results of two randomized clinical trials, PASSION and TYPHOON

Boston Scientific Corporation (NYSE: BSX) today announced four-year follow-up data from its TAXUS II paclitaxel-eluting stent system...

Initial six-month results show positive outcomes in diabetic patients; safety events for diabetic subset lower than overall patient population

International data suggests low revascularization rates for both TAXUS stent and PROMUS™ (XIENCE™ V) stent

PROMUS Stent joins market-leading TAXUS® Paclitaxel-Eluting Coronary Stent Systems

Results expected to continue to support safety and performance of Boston Scientific's second-generation drug-eluting stent system

Company also to host WCC symposia on drug-eluting stents, therapies in cardiac rhythm management and carotid artery disease

"The second quarter was a transforming one for Boston Scientific," said Jim Tobin, President and CEO

Precision™ SCS System, the first and smallest rechargeable system, achieves rapid adoption

Initial six-month results consistent with previous TAXUS registries

New system enhances diagnosis and treatment of blocked vessels and heart disorders

New Jaw Configuration Designed to Yield Larger Tissue Specimens and Improve Procedural Outcomes

Young will be responsible for all quality assurance and reliability functions for the CRM Group, including product performance reporting

A live webcast and replay of the Thursday, July 27 conference call will be available

Report analyzed data from nearly 23,000 U.S. patents and 9,000 U.S. patent applications

Company is providing safety information and retrieving a specific subset of pacemakers, cardiac resynchronization pacemakers and implantable cardioverter defibrillators

A live webcast and replay of the June 27 conference session will be available

Jury had found that J&J's Cypher® stent product infringed a Boston Scientific drug coating patent

Boston Scientific's TAXUS stent system used in more complex lesions than J&J's Cypher

A live webcast and replay of the June 13 conference session will be available

Company plans to use the net offering proceeds for general corporate purposes

Company expects to receive the offering proceeds upon closing on June 9, 2006

Technology features powerful combination of deliverability and trackability to enhance clinical versatility

Rio™ Aspiration Catheter is indicated for use in the removal of thrombi, or clots, from vessels throughout the body

In upholding the trial court, the Court of Appeals agreed that Boston Scientific's products were not within the scope of the Medtronic patents

Researchers say novel visualization capability may reduce common need for repeat procedures

Trial advances understanding of dual-chamber pacing for patients at risk of sudden cardiac death

LATITUDE® Patient Management System aligns closely with recent ACC/AHA guidelines on managing heart failure

Physician society draft recommendations reinforce LATITUDE Active Monitoring ™ capabilities

Physicians offer preview of SpyGlass™ Direct Visualization System

New second-generation training center in Brussels to help medical professionals advance standard of patient care

TAXUS benefits demonstrated in non-diabetic patient population carry over into insulin-treated diabetic patients

TAXUS VI results support positive safety and efficacy profile

Boston Scientific's second generation stent compares favorably to market leading TAXUS Express2™ stent system, even with more complex lesions

Company made the announcement at the annual Paris Course on Revascularization (EuroPCR).

Boston Scientific's second-generation stent system now approved for treatment of acute mycocardial infarction, total occlusions and in-stent restenosis

Cardiac Rhythm Management (CRM) Group is formerly Guidant's CRM business; Boston Scientific acquired Guidant on April 21

Court also upheld its earlier decision dismissing the TAXUS® Liberte™ product from the case, without prejudice

Pending approval from the Board of Directors, Dr. Baim will also join Boston Scientific's Executive Committee